Kornimate/medical-research-clean huggingface dataset:
assessment of hepatitis b virus intra-host population and host-specific immune marker diversity

Conditions: Hepatitis B; Hepatitis B, Chronic; End Stage Liver Disease; Carcinoma, Hepatocellular

Summary: in this project proposal, the investigators will investigate the genetic alterations of hepatitis b virus (hbv) strains circulating in belgian patients who developed end stage liver disease. additionally, the investigators will compare and link these data sets with three genetic factors involved in immune system response.

this project proposes to identify and characterize the genetic alterations associated with intra-host evolution of hbv from a chronically infection status to an end-stage liver disease status.

Eligibility criteria:
inclusion criteria: study group: * clinical diagnosis of advanced liver disease related to chronic hepatitis b infection (cirrhosis, hepatocellular carcinoma,..) * availability of serum samples control group: * clinical diagnosis of liver disease related to chronic hepatitis b infection in a pre-advanced stage * matched demographic and geographic characteristics to study group * availability of serum samples exclusion criteria: * liver disease caused by other hepato-tropic viruses * patients with auto-immune diseases
analgesia nociception index to explore autonomic nervous system in patients with continuous renal replacement therapy

Conditions: Critically Ill; Renal Replacement Therapy

Summary: the analgesia nociception index (ani) reflects the balance between sympathetic and parasympathetic tone. it is based on a specific interpretation of the r-r interval variation. during fluid removal by net ultrafiltration in patients with fluid overload and continuous renal replacement therapy, some data suggest that haemodynamic variation could be induced by the autonomic nervous system. the study aims to investigate ani variations in this context and their association with the haemodynamic variations observed.


Eligibility criteria:
inclusion criteria: * continuous renal replacement therapy in intensive care unit * initiation of net ultrafiltration according to the protocol of the department or to earlydry study (nct 05817539) (3 criteria required): * fluid overload \> 5% or peripheral oedema * noradrenaline equivalent \<0.5μg/kg/min * no peripheral hypoperfusion * invasive blood pressure monitoring * central venous line in superior vena cava territory * regular sinus rhythm * patient awake or richmond agitation and sedation scale \> -3 exclusion criteria: * ongoing administration of inotropes * ongoing administration of beta blockers * current administration of alpha-2 agonists * history of dysautonomia * pregnant or breast-feeding woman * mechanical circulatory assistance * opposition to participate * adults under legal protection * persons deprived of their liberty by judicial or administrative decision

Keywords: analgesia nociception index r-r interval autonomic nervous system haemodynamic fluid removal
compatibility of different injury prevention exercises in athletes

Conditions: Injury Prevention

Summary: this investigation is aimed to examine the effects of two different exercise-oriented protocols on the knee torque-angle relationship of the knee flexors. thirty two young soccer players were be randomly assigned to three groups: hamstring-eccentric (ecc, n=11), unstable-squatting (uns, n=11) or control (c, n=10). the ecc and uns groups performed eighteen sessions over 6 weeks of an injury prevention protocol, using only 3 hamstring-eccentric or unstable-squatting exercises. the angle-torque relationship was measured before and after the training intervention. voluntary isometric torque was recorded at six test angles, with participants prone (35º-100º; 0º on full extension).

this study utilized a three parallel-groups randomized controlled design, where 3 between-participant conditions, ecc, uns and c, were tested. once considered eligible for the study, all participants were familiarized with the testing procedures. participants attended the laboratory for a pre-training test session, where body mass, height and muscle functional parameters were recorded. two days after their pre-test, participants including in ecc or uns started a 6 weeks (18 sessions) training program while the control group did not perform any type of resistance training. nevertheless, during the 6 weeks intervention period all three groups continued with their normal recreationally physical activity consisting in 2 to 3 sessions per week of soccer training or friendly matches. two days after the end of the intervention period muscle function was re-tested.

Eligibility criteria:
inclusion criteria: * males, recreationally trained football players * read and sign the informed consent exclusion criteria: * participants that has undertaken a lower body resistance-training program in the preceding 6 months, * reported a previous lower limb injury

Keywords: training, soccer, eccentric, lengthening, unstable, squatting
use of a treated, devitalized and sterile umbilical cord amniotic membrane in the treatment of pip joint osteoarthritis

Conditions: Osteoarthritis Hand

Summary: the aim of this open, prospective, multicenter trial is to evaluate the use of a sterile, devitalized, processed umbilical cord amniotic membrane implant placed in joint interposition in the treatment of pip joint osteoarthritis.


Eligibility criteria:
inclusion criteria: * male or female; age between 18 and 75 years. * patient with symptomatic pipj oa. * patient treated medically for functional signs for more than 3 months, without improvement, justifying a surgical intervention. * patient with a quickdash score \> 33 points (converted to 50%). * patient with pain, at rest, in the pipj ≥ 4/10 on a vas. * patient who received the study information and provided consent. * member or beneficiary of a national health insurance plan. exclusion criteria: * pregnant or breastfeeding woman; woman without effective contraception. * patient with signs of neuropathy with functional disorders such as hyperesthesia. * patient with uncontrolled epilepsy or neuropathy that contraindicates locoregional anesthesia. * person confined by a judicial or administrative decision. * adult subjected to legal protection measures or unable to provide his/her consent.

Keywords: proximal interphalangeal joint (pipj) osteoarthritis (oa)
mechanisms underlying the regulation of impaired glucose tolerance by auricular concha electro-acupuncture

Conditions: Impaired Glucose Tolerance

Summary: impaired glucose tolerance (igt) is an abnormal metabolic state following glucose metabolic steady state but prior to diabetes. igt is an important stage during the progression of diabetes, with an underlying mechanism of insulin resistance and pancreatic β cell dysfunction. igt is one of the diseases that shows significant beneficial response to acupuncture treatment. original findings from the investigators'laboratory show that transcutaneous auricular vagus nerve stimulation (tavns) which is innervated by vagus nerve, would enhance the activity of pancreatic β cells, promote the secretion of insulin, upregulate the expression of insulin receptors in central as well as peripheral tissues, thus to improve glycometabolism. in this study, the investigators would further illuminate the mechanism of tavns at "yidan-pi" auricular acupoints on the regulation of glucose metabolism, its improvement of the igt state in rat model, as well as its regulation effect on insulin receptor expression and insulin resistance, and systematically illustrate the clinical effective of this treatment on igt, with emphasize on its influence on the concentrations of glucose and hba1c, and thus provide an effective proposal for clinical acupuncture.


Eligibility criteria:
inclusion criteria: * ages between 20 and 70 * fasting plasma-glucose(fpg) less than 7 mmol/l, or 2h p-glucose 7.8-11.1 mmol/l * anti-diabetic medication of any kind * able to provide informed consent exclusion criteria: * comorbidities that would prohibit participation in study procedures, including cardiovascular disease, hematological system disease or psychosis * females of childbearing potential who were pregnant, breast-feeding * infection within the 1 month * known or suspected abuse of alcohol or narcotics
evaluation of the cancer tracking system (catsystem)

Conditions: Cervical Cancer

Summary: cervical cancer contributes to significant preventable mortality in kenya where less than 20% of women are screened. the cancer tracking system (catsystem) is a web-based, algorithm generated tool to promote guideline adherent cervical cancer screening and retention through treatment. the goal of this project is to rigorously evaluate the efficacy, implementation, and cost-effectiveness of the catsystem to improve rates of screening, treatment, referral, and follow-up care in a matched, cluster randomized controlled trial in 10 kenyan government hospitals (5 intervention, 5 standard of care).

to help address system level barriers to cervical cancer screening, treatment, and follow-up in kenya, investigators worked with end-users (providers and patients) to develop the cancer tracking system (catsystem), a web-based, algorithm generated tool to promote guideline adherent cervical cancer screening and retention through treatment. the goal of this project is to rigorously evaluate the efficacy, implementation, and cost-effectiveness of the catsystem to improve rates of screening, treatment, referral, and follow-up care in a matched, cluster randomized controlled trial in 10 kenyan government hospitals (5 intervention, 5 standard of care). specific aims (sa) of the study are to (1) implement and evaluate the efficacy of catsystem to improve guideline adherent cervical cancer screening, treatment, referral and follow up, (2) assess feasibility and acceptability of implementation of catsystem in government run facilities using a human centered design approach, and (3) calculate the costs and cost-effectiveness of the catsystem to increase quality adjusted life years gained. cervical cancer deaths can be prevented with early detection and treatment. this study will evaluate the public health impact of the catsystem in improving cervical cancer screening, treatment, referral, follow-up, and the feasibility of scale up to other low resource settings.

Eligibility criteria:
inclusion criteria: * women above 16 years of age * access to a cell phone, * presenting for cervical cancer screening at a study hospital. exclusion criteria: * greater than 20 weeks gestation, * incarcerated patients, * women who study staff feel are unable to provide written informed consent due to impaired capacity.

Keywords: cervical cancer screening treatment of precancerous lesions treatment of invasive cervical cancer referral and retention system level intervention ehealth intervention kenya
su5416 in treating patients with advanced, metastatic, or recurrent soft tissue sarcomas

Conditions: Gastrointestinal Stromal Tumor; Sarcoma

Summary: phase ii trial to study the effectiveness of su5416 in treating patients who have advanced, metastatic, or recurrent soft tissue sarcomas. su5416 may stop the growth of soft tissue sarcomas by stopping blood flow to the tumor.

objectives: i. determine the response rate, response duration, and overall survival in patients with advanced, metastatic, or recurrent soft tissue sarcoma or gastrointestinal stromal tumor when treated with su5416. ii. determine the safety of su5416 in these patients. outline: this is a multicenter study. patients receive su5416 iv twice weekly for 4 weeks. treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity. patients are followed monthly for 3 months and then every 3 months for 1 year.

Eligibility criteria:
disease characteristics: * histologically confirmed advanced, metastatic, recurrent, or unresectable soft tissue sarcoma or gastrointestinal stromal tumor * measurable disease defined as lesions that can be measured in at least one dimension as at least 20 mm with conventional techniques or at least 10 mm with spiral ct scan * must have received prior chemotherapy with no response or progression after initial response * evidence of disease progression in past 3 months * no cns metastases or primary brain tumors patient characteristics: * age: 18 and over * performance status: ecog 0-1 * life expectancy: at least 12 weeks * wbc greater than 2,000/mm3 * platelet count greater than 100,000/mm3 * fibrin split products no greater than 0.001 mg * fibrinogen greater than 200 mg/dl * bilirubin no greater than upper limit of normal (uln) * ast/alt less than 1.5 times uln * pt/ptt less than 1.25 times uln * creatinine no greater than 1.5 mg/dl * at least 1 year since bypass surgery for atherosclerotic coronary artery disease * no uncompensated coronary artery disease * no history of myocardial infarction or unstable/severe angina in past 6 months * no severe peripheral vascular disease * no history of deep venous or arterial thrombosis in past 3 months * no history of pulmonary embolism in past 3 months * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * no diabetes mellitus * no history of bleeding diathesis * no known active retroviral disease * no aids-associated kaposi's sarcoma * no history of allergic reaction to cremophor or paclitaxel * no uncontrolled illness or psychiatric disorder that would preclude study prior concurrent therapy: * no concurrent immunotherapy * at least 3 weeks since prior chemotherapy (6 weeks since mitomycin or nitrosoureas) * no concurrent chemotherapy * at least 3 weeks since prior radiotherapy * no concurrent radiotherapy * greater than 2 weeks since prior minor surgery (greater than 4 weeks since major surgery) * no concurrent antiinflammatory drugs

Keywords: stage iii adult soft tissue sarcoma recurrent adult soft tissue sarcoma gastrointestinal stromal tumor stage iv adult soft tissue sarcoma
oral health and endometriosis: a cohort study

Conditions: Endometriosis

Summary: a survey has been conducted thanks to a questionnaire composed of 45 questions. the study group was composed of 4079 women affected by endometriosis, recruited from dedicated communities present on the social network facebook. the questionnaire investigated about: the endometriosis status, the kind of therapy, the presence of any sign and symptoms in the oral cavity, the presence of periodontal problems, the self-perception of the oral health status, the presence of other autoimmune diseases and oral hygiene and the eating habits, physical activity practiced, the life quality.

the questions were structured thanks to the collaboration of expert health professionals: gynecologist, dentist, dental hygienist, physiotherapist, dietician, psychologist to obtain targeted information on endometriosis, on the type of therapy, on any signs and symptoms in the oral cavity (perception health status, presence of periodontal problems), to investigate oral hygiene and dietary habits, physical activity, quality of life, the presence of other immune-based diseases. in the final part of the questionnaire there was a section in which women were free to tell their stories.

Eligibility criteria:
inclusion criteria: * the only inclusion criterion was being at least 18 years old exclusion criteria: * • pregnancy. * administration of antibiotics in the last 15 days prior to entry into the study or indications for antibiotic prophylaxis. * orthodontic appliances. * immunological diseases or use of drugs that can affect oral tissues (phenytoin, cyclosporine), nifedipine, chronic use of nonsteroidal anti-inflammatory drugs. * refusal to participate in the study.

Keywords: endometriosis oral health periodontitis gengivitis
the establishment of the integration of surgery and postoperative intensive recovery of patients with csm

Conditions: Cervical Myelopathy; Ossification of Posterior Longitudinal Ligament in Cervical Region

Summary: this study aims to establish the specialist consensus of the integration of posterior approach surgical treatment and postoperative intensive recovery management for csm or opll patients, and verify its safety, practicability and reliability.

in order to establish the specialist consensus of the integration of posterior approach surgical treatment and postoperative intensive recovery management, and verify its safety, practicability and reliability, this study enrolled 130 patients with csm or opll undergoing c3-7 open-door laminoplasty. patients are divided in two groups randomly. the study group has 80 patients, treated with postoperative intensive recovery management, and the control group has 50 patients. the data is collected preoperatively, at 3-month follow-up and 1-year follow-up.

Eligibility criteria:
inclusion criteria: * (1) age: 18\~70 years. (2) diagnosed as csm or opll. (3) going to receive c3-c7 open-door laminoplasty. (4) agree to join this study and sign the informed consent. exclusion criteria: * (1) anterior and posterior combined surgery. (2) posterior laminoplasty combined fusion. (3) severe osteoporosis. (4) morbid obesity. (5) patients with mental disorder. (6) patients with previous history of cervical spine surgery. (7) abnormal laboratory report of liver function, kidney function and hematologic system.(8) poor compliance. (9) patients with other surgical contraindications. (10) patients with intemperance or taking drugs. (11) patients who joined other study within the last 3 months.

Keywords: cervical myelopathy ossification of posterior longitudinal ligament intensive recovery quality of life surgical outcomes
removing transfusion dependence as a barrier to hospice enrollment

Conditions: Hematologic Malignancy; Myelodysplastic Syndromes; Acute Myeloid Leukemia; Lymphoma; Leukemia; Myeloma

Summary: hospice care at the end of life (eol) includes a multidisciplinary team that helps patients and families focus on symptom control and quality of life. for patients with "solid" (e.g. lung, breast) cancers it has been shown to improve quality of life for both patients and families. unfortunately, patients with blood cancers (e.g. leukemia, lymphoma) often delay their enrollment and receive more aggressive care at the eol. one factor in this delay is the inability for patients to receive blood transfusions while on hospice. patients with blood cancers often require frequent blood transfusions near the eol for symptom control. the structure of medicare hospice benefit makes coverage for transfusions financially unfeasible for hospice agencies, and therefore patients with blood cancers will delay enrollment onto hospice in order to continue to receive blood transfusions. the objective of this study is to evaluate whether removing this financial burden, through external funding of blood transfusions for patients while on hospice, will encourage patients with blood cancers to enroll on hospice earlier and ultimately improve their and their caregivers eol care.

the overall objective is to demonstrate the feasibility of providing blood transfusions to patients with hm enrolled on hospice, and to evaluate both eol care quality outcomes in these patients, and caregiver quality of life and perception of patient eol care quality. palliative blood transfusions will be provided to patients on this study free of cost through study funding. the hypothesis is that removing transfusion dependence as a barrier to hospice enrollment for patients with hematologic malignancies will result in improved eol care quality outcomes. this hypothesis is derived from our previous research demonstrating that for medicare beneficiaries with hm, transfusion dependence poses a significant barrier to timely hospice referral. the study design is to conduct a single-center, prospective pilot study . patients with aggressive hematologic malignancies who are hospice eligible, not pursuing further cancer directed therapy, and whose primary hematologist is planning to initiate a conversation regarding transition to hospice will be pursued for enrollment. these patients will be offered to enroll in this study in which funding will be provided to receive palliative blood transfusions while enrolled on hospice.

Eligibility criteria:
inclusion criteria: * aged 18 and older * advanced hematologic malignancies * hospice eligible as determined by their primary hematologist * have opted to forego further cancer-directed therapy. * transfusion dependent: requiring at least 2 units of blood products exclusion criteria: * patients with major psychiatric illness * patients without the ability to speak and read english

Keywords: palliative care
effect of mu-opioid receptor genetics on 3 doses of spinal morphine for postoperative analgesia after cesarean section

Conditions: Postoperative Pain

Summary: hypothesis: the response to a given dose of morphine given via a spinal anesthetic for cesarean section will be affected by the genetics of the woman's mu-opioid receptor most women undergoing elective cesarean section (cs) receive spinal anesthesia, and most receive a dose of preservative free morphine with the spinal anesthetic. spinally-administered morphine provides 16-24 hours of high quality pain relief. the dose administered is usually 75-200 micrograms, but surprisingly few dose-response studies exist. the mu-opioid receptor (oprm1 gene)is the site of action of endogenous opioid peptides and opioid analgesic drugs like morphine. there is a common genetic variant of this receptor at the 40th amino acid of the protein, with asparagine and asparate being present in different people. the less common variant (aspartate), present in 25-30% of the overall american population (higher in asian populations, lower in blacks) at codon 40 that has been shown in many studies to affect opioid analgesia. this will be a randomized, blinded study of 3 doses of spinal morphine (50, 100, 150 micrograms) given to women undergoing elective cesarean section at term pregnancy. 300 women will be studied (100 per dose). blood will be obtained for genotyping of oprm1 and other genes that may affect pain and analgesic responses. the primary outcome will be the amount of intravenous morphine patients self-administer in the 24 hours postsurgery. the primary outcome (use of intravenous morphine) will be analyzed by dose, and within each dose group by genotype of oprm1. secondary outcomes will include pain scores every 6 hours, satisfaction with analgesia, side effects (itching, nausea/vomiting) by dose and genotype. it is anticipated that there will be an interim data analysis at 150 evaluable subjects for assessment of the dose response to morphine in the overall population; then a final analysis at 300 subjects for the genetic effect assessment.


Eligibility criteria:
inclusion criteria: * healthy women undergoing elective cesarean exclusion criteria: * cardiovascular disease * analgesic medications * complications of pregnancy

Keywords: cesarean postoperative morphine genetics opioid